CILAMOX SUGAR-FREE SYRUP (amoxicillin 250mg/5mL as trihydrate) powder for oral liquid bottle Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

cilamox sugar-free syrup (amoxicillin 250mg/5ml as trihydrate) powder for oral liquid bottle

viatris pty ltd - amoxicillin trihydrate, quantity: 50 mg/ml - oral liquid, powder for - excipient ingredients: colloidal anhydrous silica; silicon dioxide; disodium edetate; sodium benzoate; xanthan gum; saccharin sodium; sorbitol; flavour - indications as at 6 november 2003: cilamox is indicated for the treatment of infections due to susceptible strains of the sensitive organisms. gram-negative: h. influenzae, e coli, pr. mirabilis, and n. gonorrhoeae. gram-positive: streptococcus species, s. pneumoniae, non-penicllinase producing staphlococci and bacillus anthracis. note 1: cilamox may be useful in instituting therapy prior to bacteriology; however, bacteriological studies to determine the causative organisms and their sensitivity to cilamox should be performed. note 2: penicillins are now generally regarded only as adjunctive to some other established first-line antibiotic therapy in the treatment and post-exposure prophylaxis of anthrax, because of concerns of constitutive and inducible beta-lactamase in bacillus anthracis. if use of amoxycillin is contemplated, appropriate bacteriological studies must be performed by a reliable and established test method. amoxycillin may then be suitable if the specific b. anthracis strain has been shown definitively to be sensitive to penicillin/amaxycillin.

Miro-Amoxicillin Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

miro-amoxicillin

miro healthcare limited - amoxicillin trihydrate 287.5mg equivalent to amoxicillin 250 mg;  ;   - capsule - 250 mg - active: amoxicillin trihydrate 287.5mg equivalent to amoxicillin 250 mg     excipient: brilliant blue fcf carmoisine croscarmellose sodium gelatin ink magnesium stearate methyl hydroxybenzoate propyl hydroxybenzoate purified water quinoline yellow sodium laurilsulfate sunset yellow fcf   titanium dioxide   - amoxicillin is indicated for the treatment of the following infections due to susceptible strains of sensitive organisms: upper respiratory infections: otitis media, pharyngitis, sinusitis and tonsillitis. lower respiratory infections: bronchitis, bronchopneumonia and lobar pneumonia. urinary tract infections: cystitis, cysto-pyelitis, urethritis, and gonococcal urethritis. prophylaxis: against ?-haemolytic (viridans group) and ?-haemolytic streptococci before dental, oral or upper respiratory tract surgery or instrumentation. prophylaxis: of bacterial endocarditis in patients with any of the following conditions: congenital cardiac malformations, rheumatic and other acquired valvular lesions, prosthetic heart valves, previous history of bacterial endocarditis, hypertrophic cardiomyopathy, surgically constructed systemic-pulmonary shunts, mitral valve prolapse with valvular regurgitation or mitral valve prolapse without valvular regurgitation but associated with thickening and/or redundancy of the valve leaflets. amoxicillin is further indicated for the treatment of cutaneous infections. in emergency cases where the causative organism is not yet identified, therapy may be initiated with amoxicillin on the basis of clinical judgement, while awaiting the results of bacteriologic studies to determine its antimicrobial sensitivity.

Miro-Amoxicillin Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

miro-amoxicillin

miro healthcare limited - amoxicillin trihydrate 575mg equivalent to amoxicillin 500 mg;  ;   - capsule - 500 mg - active: amoxicillin trihydrate 575mg equivalent to amoxicillin 500 mg     excipient: brilliant blue fcf carmoisine croscarmellose sodium gelatin ink magnesium stearate methyl hydroxybenzoate propyl hydroxybenzoate purified water quinoline yellow sodium laurilsulfate sunset yellow fcf   titanium dioxide   - amoxicillin is indicated for the treatment of the following infections due to susceptible strains of sensitive organisms: upper respiratory infections: otitis media, pharyngitis, sinusitis and tonsillitis. lower respiratory infections: bronchitis, bronchopneumonia and lobar pneumonia. urinary tract infections: cystitis, cysto-pyelitis, urethritis, and gonococcal urethritis. prophylaxis: against ?-haemolytic (viridans group) and ?-haemolytic streptococci before dental, oral or upper respiratory tract surgery or instrumentation. prophylaxis: of bacterial endocarditis in patients with any of the following conditions: congenital cardiac malformations, rheumatic and other acquired valvular lesions, prosthetic heart valves, previous history of bacterial endocarditis, hypertrophic cardiomyopathy, surgically constructed systemic-pulmonary shunts, mitral valve prolapse with valvular regurgitation or mitral valve prolapse without valvular regurgitation but associated with thickening and/or redundancy of the valve leaflets. amoxicillin is further indicated for the treatment of cutaneous infections. in emergency cases where the causative organism is not yet identified, therapy may be initiated with amoxicillin on the basis of clinical judgement, while awaiting the results of bacteriologic studies to determine its antimicrobial sensitivity.